Topic summary
25B-NBOMe
25B-NBOMe, also known as NBOMe-2C-B, Cimbi-36, or as N-(2-methoxybenzyl)-4-bromo-2,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine, 2C, and 25-NB (NBOMe) families. It is the N-(2-methoxybenzyl) derivative of 2C-B. The drug is taken sublingually, bucally, or intranasally.
It acts as a potent full agonist for the serotonin5-HT2Areceptor.
25B-NBOMe was first described in the scientific literature by Ralf Heim and colleagues at the Free University of Berlin by 1999. After 25I-NBOMe and along with 25C-NBOMe, 25B-NBOMe is one of the most widely used 25-NB psychedelics.